BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the Canaccord Genuity 30th Annual Growth Conference, to be held on August 11, 2010 in Boston. Members of the Company’s management team will present a 25 minute corporate overview on August 11 at 2:30 PM ET.
